Thomas Merlin C
Biochemistry of Diabetes Complications, Baker IDI Heart and Diabetes Institute, P.O. Box: 6492, Melbourne, Australia.
Curr Cardiol Rev. 2016;12(3):249-55. doi: 10.2174/1573403x12666160606120254.
Increasing numbers of older patients with type 2 diabetes, and their improved survival from cardiovascular events is seeing a massive increase in patients with both diabetes and heart failure. Already, at least a third of all patients with heart failure have diabetes. This close association is partly because all the major risk factors for heart failure also cluster in patients with type 2 diabetes, including obesity, hypertension, advanced age, sleep apnoea, dyslipidaemia, anaemia, chronic kidney disease, and coronary heart disease. However, diabetes may also cause cardiac dysfunction in the absence of overt macrovascular disease, as well as complicate the response to therapy. Current management is focused on targeting modifiable risk factors for heart failure including hyperglycaemia, dyslipidaemia, hypertension, obesity and anemia. But although these are important risk markers, none of these interventions substantially prevents heart failure or improves its outcomes. Much more needs to be done to focus on this issue, including the inclusion of hospital admission for heart failure as a pre-specified component of the primary composite cardiovascular outcomes and new trials in heart failure management specifically in the context of diabetes.
2型糖尿病老年患者数量不断增加,且他们因心血管事件的生存率有所提高,这使得糖尿病合并心力衰竭的患者大量增加。目前,至少三分之一的心力衰竭患者患有糖尿病。这种密切关联部分是因为心力衰竭的所有主要危险因素在2型糖尿病患者中也聚集在一起,包括肥胖、高血压、高龄、睡眠呼吸暂停、血脂异常、贫血、慢性肾病和冠心病。然而,糖尿病在无明显大血管疾病的情况下也可能导致心脏功能障碍,以及使治疗反应复杂化。目前的管理重点是针对心力衰竭的可改变危险因素,包括高血糖、血脂异常、高血压、肥胖和贫血。但是,尽管这些是重要的风险标志物,但这些干预措施均不能实质性地预防心力衰竭或改善其预后。需要做更多工作来关注这个问题,包括将心力衰竭住院作为主要复合心血管结局的预先指定组成部分,以及专门针对糖尿病背景下的心力衰竭管理开展新试验。